Turkish Version of the Glaucoma Quality of Life-15 Questionnaire

Sponsor
Acibadem University (Other)
Overall Status
Completed
CT.gov ID
NCT03967145
Collaborator
Haydarpasa Numune Training and Research Hospital (Other)
127
1
9.2
13.9

Study Details

Study Description

Brief Summary

Glaucoma is a disease with irreversible loss of visual field and optic neuropathy and is the most important cause of irreversible vision loss after cataract in the world. Although clinical evaluations reveal the level of glaucoma quantitatively, it is necessary to evaluate the impact of this pathology on daily functions and quality of life with a holistic perspective and to provide appropriate advice to patients according to the information obtained. Glaucoma Quality of Life -15 Questionnaire (GQoL-15) was developed by Nelson et al. in 2003 to evaluate the quality of life of glaucoma patients. The aim of this study is to translate GQoL-15 into Turkish and evaluate its test-retest reliability for Turkish-speaking population.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Determining quality of life

Study Design

Study Type:
Observational
Actual Enrollment :
127 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Reliability and Validity of the Turkish Version of the Glaucoma Quality of Life-15 Questionnaire
Actual Study Start Date :
May 27, 2019
Actual Primary Completion Date :
Mar 1, 2020
Actual Study Completion Date :
Mar 1, 2020

Outcome Measures

Primary Outcome Measures

  1. Glaucoma Quality of Life 15 Questionnaire total score [6 months]

    GQoL-15 total score was got after calculate the all subscale values. Subscales are as; 1) Central and near vision (two questions); 2) Peripheral vision (six questions); 3) Dark adaptation (six questions); 4) Outdoor mobility (one question). The item responses for each factor are marked on a five-point scale (1 meaning no difficulty and 5 meaning severe difficulty), 0 is marked if the participant does not perform the activity because of non-visual causes. Higher GQL-15 total scores and subscale scores are reveals lower QoL.

  2. 25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ 25) [6 months]

    NEI-VFQ 25 total score was got after calculate the all values. It is comprised of 25 items which are; general health and vision, ocular pain, difficulty with vision activities, distance-vision activities, limitation of social functioning, mental health problems, role limitations, dependency on others, driving difficulties, difficulty with color vision and difficulty with peripheral vision. A total score of NEI-VFQ 25 is generated by averaging the scores of all subscales except general health. The item responses for factors are marked on a five or six point scale. Subscale score can be calculated, overall total lower score indicates better vision-related QoL.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 60 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Diagnosis of primary open angle glaucoma more than 6 months with visual field tests,

  • Have the sufficient cognitive level to answer the scale questions.

Exclusion Criteria:
  • To have retinal or optic nerve pathologies that may cause loss of visual field or decrease in visual field except glaucoma,

  • To undergo eye surgery in the last 3 months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yücel Öztürk İstanbul Turkey

Sponsors and Collaborators

  • Acibadem University
  • Haydarpasa Numune Training and Research Hospital

Investigators

  • Principal Investigator: Özgül Öztürk, Acibadem University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Özgül Öztürk, Principal Investigator, Acibadem University
ClinicalTrials.gov Identifier:
NCT03967145
Other Study ID Numbers:
  • ATADEK 2019-7/2
First Posted:
May 30, 2019
Last Update Posted:
Apr 8, 2020
Last Verified:
Apr 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 8, 2020